Mattingly, T. Joseph II http://orcid.org/0000-0001-7786-5780
Levy, Joseph F. http://orcid.org/0000-0002-9317-5306
Slejko, Julia F. http://orcid.org/0000-0001-6900-9220
Onwudiwe, Nneka C.
Perfetto, Eleanor M. http://orcid.org/0000-0001-8150-1058
Article History
First Online: 12 May 2018
Compliance with Ethical Standards
:
: T Joseph Mattingly II has received funding from ALK, Inc. and Bristol Myers Squibb for research unrelated to this study, and consulting fees for advisory boards from Summit Therapeutics and Paratek Pharmaceuticals, also unrelated to this study. Joseph F. Levy receives postdoctoral fellowship support from Merck & Co. Inc. Julia F. Slejko has received funding for research from Takeda Pharmaceuticals USA, Inc., Novartis Pharmaceuticals Corporation, and PhRMA Foundation, unrelated to this study, as well as consulting fees from Pfizer, Inc., also for work unrelated to this study. Nneka C. Onwudiwe has no conflicts of interest, however wishes to add the following statement: ‘This article reflects the views of the author and should not be construed to represent the FDA’s views or policies’. Eleanor M. Perfetto has no conflicts of interest to disclose.
: All authors declare that they received no financial support for this study.
: The model developed within this study is available from the corresponding author upon request. All data inputs are described in the paper.